Jin Seok Ahn

2.7k total citations · 1 hit paper
56 papers, 2.2k citations indexed

About

Jin Seok Ahn is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Jin Seok Ahn has authored 56 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 7 papers in Surgery. Recurrent topics in Jin Seok Ahn's work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (23 papers) and Colorectal Cancer Treatments and Studies (16 papers). Jin Seok Ahn is often cited by papers focused on Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (23 papers) and Colorectal Cancer Treatments and Studies (16 papers). Jin Seok Ahn collaborates with scholars based in South Korea, United States and Switzerland. Jin Seok Ahn's co-authors include Keunchil Park, Myung‐Ju Ahn, Jong‐Mu Sun, Dae Ho Lee, Sang‐We Kim, Jae‐Won Lee, Cheolwon Suh, Jeeyun Lee, Winnie Yeo and Sook Jung Jo and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Jin Seok Ahn

55 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

2012 611 citations Keunchil Park, Sang‐We Kim et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jin Seok Ahn

Since Specialization

Citations

This map shows the geographic impact of Jin Seok Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin Seok Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin Seok Ahn more than expected).

Fields of papers citing papers by Jin Seok Ahn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin Seok Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin Seok Ahn. The network helps show where Jin Seok Ahn may publish in the future.

Co-authorship network of co-authors of Jin Seok Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Jin Seok Ahn. A scholar is included among the top collaborators of Jin Seok Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin Seok Ahn. Jin Seok Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Establishing Regional Aβ Cutoffs and Exploring Subgroup Prevalence Across Cognitive Stages Using BeauBrain Amylo^® 2025 ·Dementia and Neurocognitive Disorders ·Seongbeom Park, (unknown), (unknown), (unknown), Jin Seok Ahn, (unknown), Hyemin Jang, Duk L. Na, Hee Jin Kim, Seung Hwan Moon, Jun Pyo Kim, Sang Won Seo, Jaeho Kim, Kichang Kwak	0
2	Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Soohyun Hwang, (unknown), Boram Lee, (unknown), Hye Min Kim, (unknown), Sehhoon Park, (unknown), Jong‐Mu Sun, Jin Seok Ahn, (unknown), Yoon‐La Choi, Chang Ho Ahn, (unknown), Chan‐Young Ock, Se-Hoon Lee	1
3	OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC) 2024 ·Journal of Thoracic Oncology ·Hidehito Horinouchi, Benjamin Solomon, Yi‐Long Wu, (unknown), Matomo Nishio, Jin Seok Ahn, D.H. Lee, J.-S. Lee, Wen‐Zhao Zhong, Maximilian J. Hochmair, Igor Bondarenko, (unknown), Achim Rittmeyer, Beiying Ding, Thorsten Ruf, (unknown), Astrid Scalori, Rafał Dziadziuszko	1
4	Clinical Outcomes of Maintenance Durvalumab After Definitive Concurrent Chemoradiotherapy in Unresectable Locally Advanced Stage III NSCLC According to EGFR and ALK Status: Korean Cancer Study Group LU-22-18 2024 ·JTO Clinical and Research Reports ·(unknown), (unknown), Young Saing Kim, Keon Uk Park, Jang Ho Cho, Hong-Sik Kim, Ki Hyeong Lee, (unknown), Il Hwan Kim, Kyung Hee Lee, Gyeong‐Won Lee, Seong Yoon Yi, Byeong‐Cheol Ahn, Min-Young Lee, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Jin Seok Ahn, Se‐Hoon Lee, Myung‐Ju Ahn	1
5	Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): Data from ALINA. 2024 ·Journal of Clinical Oncology ·Makoto Nishio, Yi‐Long Wu, Fabrice Barlési, Jin Seok Ahn, (unknown), Jong-Seok Lee, Wen‐Zhao Zhong, Hidehito Horinouchi, Maximilian J. Hochmair, Hiroshi Tanaka, Maciej Głogowski, Achim Rittmeyer, Mary J. Fidler, Anna Wrona, Carla Mamolo, Andrés F. Cardona, Thorsten Ruf, Vlatka Smoljanović, Benjamin Solomon	1
6	MA13.11 Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial 2023 ·Journal of Thoracic Oncology ·Sojung Park, Hee Kyung Ahn, (unknown), Young Joo Min, Hyun Ae Jung, Jong‐Mu Sun, SH Lee, Jin Seok Ahn, Myung‐Ju Ahn, (unknown), Sun Moon Kim, (unknown), B.C. Cho, Min Hee Hong	2
7	Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small cell lung cancer (NSCLC). 2018 ·Journal of Clinical Oncology ·Sai‐Hong Ignatius Ou, Leena Gandhi, Shirish M. Gadgeel, Fabrice Barlési, James Chih‐Hsin Yang, Luigi De Petris, Dong‐Wan Kim, Ramaswamy Govindan, Anne‐Marie C. Dingemans, Lucio Crinò, H. Léna, Sanjay Popat, Jin Seok Ahn, Éric Dansin, Ali Zeaiter, Bárbara Müller, H. Johannsdottir, Bogdana Balas, Peter N. Morcos, Alice T. Shaw	5
8	Drug shortages in developed countries—reasons, therapeutic consequences, and handling 2014 ·European Journal of Clinical Pharmacology ·(unknown), Jin Seok Ahn	47
9	A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy 2013 ·Lung Cancer ·Jin Seok Ahn, Ki Hyeong Lee, Jong‐Mu Sun, Keunchil Park, Eun‐Suk Kang, Eun Kyung Cho, Dae Ho Lee, Sang‐We Kim, Gyeong‐Won Lee, Jin‐Hyoung Kang, Jong Seok Lee, Jae‐Won Lee, Myung‐Ju Ahn	26
10	Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non–Small-Cell Lung Cancer 2013 ·Journal of Thoracic Oncology ·Hee Kyung Ahn, Kyeongman Jeon, Hongseok Yoo, Boram Han, Su Jin Lee, (unknown), (unknown), Sang Yun Ha, (unknown), Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park	31
11	Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation 2012 ·Cancer Chemotherapy and Pharmacology ·(unknown), Lee Chun Park, Jun Ho Ji, Silvia Park, (unknown), (unknown), Yoon‐La Choi, Jungho Han, Jong‐Mu Sun, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	15
12	Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer 2012 ·Lung Cancer ·Ha Yeon Lee, Hee Kyung Ahn, Ji Yun Jeong, Mi Jung Kwon, Jungho Han, Jong‐Mu Sun, Jin Seok Ahn, Keunchil Park, Yoon‐La Choi, Myung‐Ju Ahn	31
13	Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy 2011 ·Journal of Thoracic Oncology ·Jong‐Mu Sun, Joungho Han, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	100
14	Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection of Patients for Maintenance Therapy 2010 ·Journal of Thoracic Oncology ·Jong‐Mu Sun, Joon Oh Park, Young‐Woong Won, Jung-Hoon Kim, Jina Yun, Jeeyun Lee, Winnie Yeo, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park	25
15	The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients 2010 ·Journal of Cancer Research and Clinical Oncology ·Jong‐Mu Sun, Young‐Woong Won, Seung Tae Kim, (unknown), Yoon‐La Choi, Jeeyun Lee, Winnie Yeo, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	34
16	Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy 2010 ·Cancer ·Seung Tae Kim, Jeeyun Lee, Jeonghoon Kim, Young‐Woong Won, Jong‐Mu Sun, Jina Yun, Winnie Yeo, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn	32
17	New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy 2010 ·Lung Cancer ·Ho Yun Lee, Kyung Soo Lee, Myung‐Ju Ahn, Hye Sun Hwang, Ju Won Lee, Keunchil Park, Jin Seok Ahn, Tae Sung Kim, Chin A Yi, Myung Jin Chung	44
18	Erlotinib Monotherapy for Stage IIIB/IV Non-small Cell Lung Cancer: A Multicenter Trial by the Korean Cancer Study Group 2009 ·Journal of Thoracic Oncology ·Ji Eun Uhm, (unknown), Myung‐Ju Ahn, Jeeyun Lee, Jin Seok Ahn, (unknown), Heung-Tae Kim, (unknown), Jin‐Hyoung Kang, Y. Choi, Hong Song, Se Hoon Park, (unknown), Sang Won Shin, (unknown), Keunchil Park	24
19	Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Sarah Park, (unknown), Eun Yoon Cho, Young Mog Shim, Jinkook Kim, Hyo Song Kim, Jeeyun Lee, Winnie Yeo, Jin Seok Ahn, Keunchil Park, Pasi A. Jänne, Myung‐Ju Ahn	126
20	Solitary Dural Extramedullary Plasmacytoma With inv(9)(p13q21) 2004 ·American Journal of Clinical Oncology ·Keun Seok Lee, Jung-Ae Lee, (unknown), (unknown), Jin Seok Ahn, Dae Young Zang, (unknown), Se-Hyuck Park, (unknown), (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact